News Release

Shock treatment can kill -- Clinical trial shows how 'standard' procedure results in children's deaths

Peer-Reviewed Publication

BMC (BioMed Central)

Results from the Fluid Expansion as Supportive Therapy (FEAST) trial in East Africa show that children who are given fluid to treat shock have an increased risk of death due to cardiovascular collapse at 48 hours. These findings in BioMed Central's open access journal BMC Medicine challenge the generally held idea that early and rapid reversal of shock by fluid resuscitation translates into longer-term survival benefits.

The FEAST trial was conducted in six African hospitals across Kenya, Tanzania and Uganda without intensive care facilities. It included 3000 children with shock caused by conditions including sepsis and malaria but excluded children with gastroenteritis, burns, who had undergone surgery or had severe malnutrition. All the children in the trial received standard treatments, depending on their illness including antibiotics, antimalarials, anticonvulsants, glucose or whole blood if anemic, but were randomly assigned to receiving fluid resuscitation or to a control group without fluid resuscitation.

Prof Kathryn Maitland, from the Wellcome Trust Centre for Clinical Tropical Medicine at Imperial College London, who led this study explained, "The children who were given this treatment (boluses) initially responded well compared to the control group. However, this did not translate into a better recovery at 48 hours - more children died in the group receiving boluses. The main cause of death, rather than fluid overload, was cardiovascular collapse."

This is surprising given that this treatment is standard practice elsewhere. The research team involved in this trial believe that in settings where there is a lack of intensive care facilities 'standard' procedures, such as fluid resuscitation, should not necessarily be used, especially when they have not been properly tested in clinical trials.

Commenting on this study Prof John Myburgh, from the University of New South Wales and The George Institute for Global Health, takes this one stage further and recommends that fluid resuscitation should be used with the same care as any potentially lethal drug, "Studies are beginning to show cracks in fluid resuscitation therapy and that careful monitoring is needed as well as a better understanding of dose and the way the therapy is given. The compelling results of this study from Africa question the wisdom of fluid bolus as therapy not only in pediatric patients but also in all critically ill patients."

This article marks the launch of an article collection on Medicine for Global Health in BMC Medicine. The collection will focus on public health initiatives, the development of health care policies, management of infectious and non-communicable diseases, cost-effectiveness studies and evidence-based guidelines which are needed to address the global burden of disease.

###

Media contact

Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: +44 (0) 20 3192 2370
Mob: +44 (0) 778 698 1967
Email: hilary.glover@biomedcentral.com

Notes

1. Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial

Kathryn Maitland, Elizabeth C George, Jennifer A Evans, Sarah Kiguli, Peter Olupot-Olupot, Samuel O Akech, Robert O Opoka, Charles Engoru, Richard Nyeko, George Mtove, Hugh Reyburn, Bernadette Brent, Julius Nteziyaremye, Ayub Mpoya, Natalie Prevatt, Cornelius M Dambisya, Daniel Semakula, Ahmed Dungu, Vincent Okunny, Ronald Wokulira, Molline Timbwa, Benedict Otii, Michael Levin, Jane Crawley, Abdel G Babiker, Diana M Gibb and FEAST trial group BMC Medicine 2013, 11:68 doi:10.1186/1741-7015-11-68

Commentary

Causes of death after fluid bolus resuscitation: new insights from FEAST
John Myburgh and Simon Finfer
BMC Medicine 2013, 11:67 doi:10.1186/1741-7015-11-67

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request on the day of publication.

2. BMC Medicine is the flagship medical journal of the BMC series, publishing original research, commentaries and reviews that are either of significant interest to all areas of medicine and clinical practice, or provide key translational or clinical advances in a specific field. @BMCMedicine

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. @BioMedCentral

4. The article collection Medicine for Global Health in BMC Medicine can be found here http://www.biomedcentral.com/bmcmed/series/medicine_for_global_health

5. The FEAST trial was funded by the Medical Research Council (provided through the MRC DFID concordat). The Medical Research Council has been at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers' money in some of the best medical research in the world across every area of health. Twenty-nine MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomized controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. http://www.mrc.ac.uk


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.